Eli Lilly's oral GLP-1 (Foundayo) is clearing safety hurdles. This signals the end of the 'cold chain' logistics nightmare and the beginning of mass-market oral adoption.
Build a 'Pill-to-Pill' transition platform for the 300M potential users moving from injectables to Foundayo. Use Beehiiv for a paid newsletter ($20/mo) providing transition protocols and a Carrd landing page to capture the 'waitlist' for oral generics. Mitigate the 2026 patent cliff by focusing on the 'protocol' and 'coaching' rather than the drug itself. The money isn't in the pill; it's in the migration.
Oral delivery expands the market by 3-4x by removing the 'needle hurdle' and simplifying shipping for solo founders.
Primary observations behind the opportunity thesis.
Eli Lilly's oral GLP-1 (Foundayo) is clearing safety hurdles. This signals the end of the 'cold chain' logistics nightmare and the beginning of mass-market oral adoption.
Open signalReceipts, citations, and captured media assets tied to this opportunity.
Eli Lilly's oral GLP-1 (Foundayo) is clearing safety hurdles. This signals the end of the 'cold chain' logistics nightmare and the beginning of mass-market oral adoption.
Open sourcehttps://www.fiercepharma.com/pharma/lilly-answers-fdas-call-more-foundayo-safety-info-plotting-diabetes-filing-parallel
Open sourceRelevant companies, patterns, industries, and technologies connected to this opportunity.
Country and region facets attached to the opportunity.
Accepted and candidate claims attached to this opportunity.
Build a 'Pill-to-Pill' transition platform for the 300M potential users moving from injectables to Foundayo. Use Beehiiv for a paid newsletter ($20/mo) providing transition protocols and a Carrd landing page to capture the 'waitlist' for oral generics. Mitigate the 2026 patent cliff by focusing on the 'protocol' and 'coaching' rather than the drug itself. The money isn't in the pill; it's in the migration.
Oral delivery expands the market by 3-4x by removing the 'needle hurdle' and simplifying shipping for solo founders.
Oral is the endgame. Shipping pills is 100x easier than shipping refrigerated needles.
The 2026 semaglutide patent expiry will trigger a generic price war that makes branded orals a tough sell.